Thrombocytopenia in preterm infants born to mothers with systemic lupus erythematosus: a retrospective cohort study
View abstract on PubMed
Summary
This summary is machine-generated.Neonatal thrombocytopenia affects preterm infants of mothers with systemic lupus erythematosus (SLE), with most cases resolving. Maternal hypertensive disorders of pregnancy increase risk, while hydroxychloroquine use is protective.
Area Of Science
- Neonatal Medicine
- Immunology
- Perinatology
Background
- Thrombocytopenia in preterm infants born to mothers with systemic lupus erythematosus (SLE) is not well understood.
- Limited data exists on platelet dynamics, risk factors, and outcomes in this population.
Purpose Of The Study
- To determine the incidence, timing, and severity of thrombocytopenia in preterm infants of mothers with SLE.
- To identify maternal and neonatal risk factors associated with thrombocytopenia.
- To evaluate the association between thrombocytopenia and adverse neonatal outcomes.
Main Methods
- A retrospective study of 154 preterm infants born to mothers with SLE admitted to Shanghai Children's Medical Center (2014-2024).
- Logistic regression analysis was employed to identify risk factors and outcomes related to neonatal thrombocytopenia.
Main Results
- Thrombocytopenia occurred in 32.5% of infants, with 4.6% experiencing severe cases. The condition peaked on postnatal days 4-5.
- Protective factors included late/moderate prematurity and maternal hydroxychloroquine use. Maternal hypertensive disorders of pregnancy (HDP) increased risk.
- Thrombocytopenia was linked to higher risks of intracranial hemorrhage and late-onset sepsis.
Conclusions
- Preterm infants exposed to maternal SLE often develop thrombocytopenia, but it is typically self-limiting.
- Gestational age, maternal HDP, and hydroxychloroquine use are key factors influencing thrombocytopenia.
- Neonatal thrombocytopenia in this cohort is significantly associated with increased morbidity.

